There are studies that have established the association of CSF YKL-40 levels with core biomarkers of Alzheimer’s disease such as t-tau and p-tau proteins; increased levels of this biomarker may be related to disease progression. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.